皮肤结核一例

患者,女,64岁.颈部斑块结节8年,逐渐增大.患者8年前患乳腺癌,手术切除治疗.曾诊断为毛囊炎、孢子丝菌病、乳腺癌皮肤转移等,给予相应治疗未愈.组织病理学检查:真皮内结核性肉芽肿,结节中央可见干酪样坏死,抗酸染色阳性,PAS染色阴性,真菌培养阴性,PPD(+++).抗结核治疗后皮疹明显消退.     

APC介入治疗支气管结核的临床疗效探讨

目的探讨氩等离子体凝固(argon plasma coagulation,APC)介入治疗支气管结核的临床疗效。方法对40例确诊支气管结核的患者实施经可弯曲电子支气管镜氩气刀介入治疗,并观察其疗效。结果40例治疗1～4次,平均1.9次,经支气管镜复查,显效30例,占75%;有效10例,占25%;总有效率100%。不良反应:治疗中22例有轻微刺激性呛咳,4例感觉局部烧灼痛,未发生支气管壁坏死、穿孔、气胸、纵隔气肿等并发症。结论APC介入治疗支气管结核,在解除支气管阻塞、加速病灶的吸收及组织再生和修复方面疗效确切,痰菌阴转率及肺不张治愈率均较高,能缓解支气管狭窄后遗症,安全性高,不良反应小,有较好的临床应用价值。     

Molecular characteristics of rifampin and isoniazid resistant Mycobacterium tuberculosis strains from Beijing, China

Background China is one of the high burden countries of Mycobacterium tuberculosis （TB） infection globally, with high incidence and mortality. We studied the molecular characteristics of rifampin （RIF） and isoniazid （INH） resistant Mycobacterium tuberculosis strains from Beijing, China, in order to find out the genetic marker for rapid detection of specific drug resistance. Methods Forty pansusceptible and 81 resistant strains of Mycobacterium tuberculosis isolated from Beijing, China during 2002-2005 were analyzed. The modified rifampin oligonucleotide （RIFO） assay based on reverse line blot hybridization was used to detect mutations in the 81 bp hot-spot region of rpoB gene, which is associated with RIF resistance. The INH resistance associated genes, regulatory region mab-inhA （-15C/T） and structural gene katG S315T were detected by reverse line blot hybridization and PCR-restriction fragment length polymorphism （RFLP） method respectively. All the strains were typed by spoligotying and the Beijing genotype was further subdivided by NTF locus analysis. The distribution of drug resistance associated mutations in the above genes was compared in these groups. Results Sixty-five （91.5%） of 71 RIF resistant and 52 （92.9%） of 56 multidrug-resistant （MDR, i.e. resistant to at least RIF and INH） strains were found to harbor mutations in the rpoB hot-spot region. No mutation was detected in RIF sensitive strains. The specificity and sensitivity of the modified RIFO assay were 100% and 91.5%, respectively, katG315 AGC〉ACC and inhA-15C〉T mutations were found in 40 （60.6%） and 10 （15.2%） of 66 INH resistant strains, respectively; 7.6% of INH-resistant strains had mutations in both of these genes. Therefore, a combined use of both katG315 and inhA-15 identified 68.2% of INH-resistant strains. The Beijing genotype accounted for 91.7% of total strains and was further subdivided into ＂modern＂ （76.6%） and ＂ancestral＂ （23.4%） group. There is no significant difference between ＂ancestral＂ and ＂modern＂ group in prevalance of drug resistance-associated gene mutations. Conclusions The hot-spot region of rpoB gene can be used as genetic marker for detection of RIF resistant strains; a combined use of both katG315 and inhA-15 can improve the detection rate of I NH resistant strains; the Beijing genotype is prevalent in Beijing, China; the modified RIFO assay can be a practical tool for rapid detection of RIF resistant and MDR isolates in the routine diagnostic work.     

1040株人型结核分枝杆菌耐药性分析

目的分析研究汕头市第三人民医院2012~2013年肺结核患者结核分枝杆菌耐药性。方法对汕头市第三人民医院2012~2013年收集的结核分枝杆菌用WHO推荐的比例法进行异烟肼(H)、利福平(R)、链霉素(S)、乙胺丁醇(E)、左氧氟沙星(Lfx)、丙硫异烟胺(Pto)、卷曲霉素(Cm)、丁胺卡那(Am)、对氨基水杨酸(PAS)和卡那霉素(Km)的耐药性检测。结果2012年458株结核分枝杆菌中有135株耐药,总耐药率为29.5%(135/458);耐多药(MDR)率为14.4%(66/458)。耐单药顺位从高到低依次为H、S、R、E、Lfx、Pto、Cm、Am、PAS和Km。2013年582株结核分枝杆菌中有198株耐药,总耐药率为34.0%(198/582);耐多药(MDR)率为16.1%(94/582)。耐单药顺位从高到低依次为S、H、R、E、Lfx、Km、Cm、Am、PAS和Pto。结论结核分枝杆菌的耐药率仍然较高,临床应加强监测,指导防控工作和临床合理用药。     

多重PCR法检测结核分枝杆菌耐药基因研究

目的:建立多重PCR法快速检测结核分枝杆菌耐药基因。方法:采用多重聚合酶链反应(PCR)同时扩增46株结核分枝杆菌临床分离株、48株北京标准菌株、40例耐药及40例非耐药的结核分枝杆菌临床分离菌株的inhA、katG、rpoB、IS1081等基因并采用测序的方法进行验证。结果:所有耐药样本基因(包括利福平、异烟肼耐药基因)及野生型菌株均被成功扩增。结论:应用多重PCR技术可同时快速检测结核分枝杆菌耐药基因。     

Impact of on-site Xpert on TB diagnosis and mortality trends in Uganda

SETTING:Since 2012, Uganda expanded the Xpert^® MTB/RIF network for diagnosis of TB.OBJECTIVES:We compared TB care cascades at health facilities with on-site Xpert vs. facilities that accessed the assay through specimen referral.DESIGN:We analysed secondary aggregate data of the National TB and Leprosy Program (NTLP) from 2016 to 2019. We computed the proportions of notified TB cases and mortality ratios in relation to the estimated TB burden.RESULTS:TB case notifications per annum increased from 24,287 in 2016 to 30,739 in 2019, and the proportion of cases diagnosed at facilities with on-site Xpert testing increased from 62% (15,070/24,287) to 81% (24,829/30,739) (P < 0.001). TB mortality at facilities with on-site Xpert decreased from 8.6% (1,302/15,070) to 7.8% (1,938/24,829) (P = 0.41), while it increased at facilities without on-site Xpert from 6.9% (638/9,217) to 8.8% (521/5,910) (P = 0.23). Furthermore, mortality among TB-HIV co-infected patients at facilities with on-site Xpert dropped from 5.0% (760/15,070) in 2016 to 4.8% (1,187/24,826) in 2019 (P = 0.84) compared to 4.4% (407/9,217) in 2016 to 5.3% (315/5,910) in 2019 (P = 0.57).CONCLUSION:Wider installation and decentralisation of Xpert leads to increased case-finding. However, the impact on reduction in mortality remains limited. Interventions to address TB-related mortality in addition to Xpert roll-out are required.     

Incidence and prevalence of pulmonary tuberculosis among patients with type 2 diabetes mellitus: a systematic review and meta-analysis

BackgroundThe epidemic of type 2 diabetes mellitus (T2DM) poses a great challenge to pulmonary tuberculosis (PTB) control. However, the incidence and prevalence of PTB among T2DM patients has not been fully determined. This meta-analysis aimed to provide the estimation on the global incidence and prevalence of PTB among T2DM patients (T2DM-PTB).MethodsOnline databases including Web of Science, PubMed, China National Knowledge Infrastructure and Cochrane Library were searched for all relevant studies that reported the incidence or prevalence of T2DM-PTB through 31 January 2022. Pooled incidence and prevalence of T2DM-PTB with 95% confidence interval (CI) was estimated by the random-effect model. All statistical analyses were performed using R software.ResultsA total of 24 studies (14 cohort studies, 10 cross-sectional studies) were included. The pooled incidence and prevalence of T2DM-PTB were 129.89 per 100,000 person-years (95% confidence interval (CI): 97.55–172.95) and 511.19 per 100,000 (95% CI: 375.94–695.09), respectively. Subgroup analyses identified that the incidence of T2DM-PTB was significantly higher in Asia (187.20 per 100,000 person-years, 95% CI: 147.76–237.17), in countries with a high TB burden (172.04 per 100,000 person-years, 95% CI: 122.98–240.68) and in studies whose data collection ended before 2011 (219.81 per 100,000 person-years, 95% CI: 176.15–274.28), but lower in studies using International Classification of Diseases-10 codes (73.75 per 100,000 person-years, 95% CI: 40.92–132.91). The prevalence of T2DM-PTB was significantly higher in countries with a high TB burden (692.15 per 100,000, 95% CI: 468.75–1022.04), but lower in Europe (105.01 per 100,000, 95% CI: 72.55–151.98).ConclusionsThis systematic review and meta-analysis suggests high global incidence and prevalence of PTB among T2DM patients, underlining the necessity of more preventive interventions among T2DM patients especially in countries with a high TB-burden.

Key messages

• A total of 24 studies (14 cohort studies, 10 cross-sectional studies) containing 2,569,451 T2DM patients were included in this meta-analysis.
• The pooled incidence and prevalence of T2DM-PTB are 129.89 per 100,000 person-years (95% CI: 97.55–172.95) and 511.19 per 100,000 (95% CI: 375.94–695.09) respectively.
• The incidence of T2DM-PTB was significantly higher in Asia, in countries with a high TB burden and in studies whose data collection ended before 2011, but lower in studies using International Classification of Diseases-10 codes.
• The prevalence of T2DM-PTB was significantly higher in countries with a high TB-burden, but lower in Europe.

     

Hodgkin Lymphoma after Disseminated Mycobacterium genavense Infection,Germany

Mycobacterium genavense infection, a rare nontuberculous mycobacteria infection, occurs in heavily immunocompromised patients (i.e., those with advanced HIV disease, genetic disorders, or acquired immunologic disorders and those undergoing immunosuppressive therapy). We report a case of disseminated M. genavense infection preceding Hodgkin lymphoma in a patient without obvious risk factors for this infection.     

Chronic Pulmonary Disease Caused by Tsukamurella toyonakaense

Unidentified Mycobacterium species are sometimes detected in respiratory specimens. We identified a novel Tsukamurella species (Tsukamurella sp. TY48, RIMD 2001001, CIP 111916^T), Tsukamurella toyonakaense, from a patient given a misdiagnosis of nontuberculous mycobacterial pulmonary disease caused by unidentified mycobacteria. Genomic identification of this Tsukamurella species helped clarify its clinical characteristics and epidemiology.     

100例耳鼻咽喉及颈淋巴结结核的综合表现和疗效分析

目的 分析耳鼻咽喉及淋巴结结核的综合表现以及临床疗效.方法 资料选自2011年10月-2012年12月收住在我院被确诊为耳咽喉以及颈淋巴结结核患者100例,通过反映出的局部的临床表现分别进行全身、局部、免疫治疗,观察临床疗效.结果 100例患者中经过全身的基础、免疫、局部相结合治疗,治疗3个月以后,患者的耳鼻咽喉及颈部的淋巴结节症状减轻或者消失,术后伤口的愈合良好,无任何并发症发生,且治愈率为100％.结论 对于耳鼻咽喉及颈部淋巴结结核患者应该尽早确诊,早期采用规范的抗结核治疗的方法是取得治疗该病的关键因素.